Clinical Trial Update: Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) [Phase 2]

View source ↗

Summary

Extension phase 2 study update evaluating the long-term safety and efficacy of luspatercept in β-thalassemia patients previously enrolled in a prior trial, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thalassemia

Drugs mentioned

• Luspatercept (luspatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: β-Thalassemia | Phase 2 | Status: COMPLETED | Results posted: 2024-07-18